T1	intervention 78 122	bevacizumab in combination with capecitabine
T2	control 126 136	paclitaxel
T3	age 410 419	â‰¥18 years
T4	total-participants 829 832	561
T5	intervention-participants 850 853	284
T6	control-participants 862 865	277
T7	outcome 993 1017	Treatment-related events
T8	iv-bin-percent 1030 1035	85.2%
T9	cv-bin-percent 1048 1053	78.0%
T10	outcome 1075 1082	Fatigue
T11	iv-bin-percent 1109 1114	30.6%
T12	cv-bin-percent 1122 1127	23.5%
T13	outcome 1140 1164	hand-foot syndrome (HFS)
T14	cv-bin-percent 1187 1192	49.5%
T15	iv-bin-percent 1200 1204	2.5%
T16	outcome 1213 1222	Diarrhoea
T17	iv-bin-percent 1231 1235	0.4%
T18	cv-bin-percent 1244 1248	1.4%
T19	outcome 1254 1272	pulmonary embolism
T20	iv-bin-percent 1281 1285	0.7%
T21	cv-bin-percent 1294 1298	1.1%
